January 27th 2023
Take a look at 5 of the most-anticipated FDA pending approvals expected in 2023 that neurological researchers and clinicians should keep an eye out on.
April 19th 2021
The 2021 AAN Meeting Hot Topics plenary focused on neurological facets of COVID-19, and featured insight from Anthony Fauci, MD, of NIAID, and Walter Koroshetz, MD, of NINDS, among others.
January 5th 2021
A recent analysis of UnitedHealthcare insurance claims revealed increases of almost 200% for some services between 2001 and 2016.
December 23rd 2020
PTC Therapeutics announced the initiation of its third study of 2020 investigating vatiquinone.
December 16th 2020
These data follow a recent announcement from Sio Gene Therapies that the first patient in the high-dose cohort has been dosed.
Unmet Needs in NMOSD
Mitzi Williams, MD; Mirla Avila, MD; and Michael Levy, MD, PhD, highlight gaps in care in NMOSD therapy.
Goals of Therapy for NMOSD
Drs Mirla Avila, Mitzi Williams, Michael Levy, and Michael Yeaman provide insight on goals of therapy and the importance of mental health and symptom management for patient populations with NMOSD.
Treatment Selection for NMOSD Patient Populations
Mitzi Williams, MD; Mirla Avila, MD; and Michael Levy, MD, PhD, discuss their approach to optimizing treatment selection when it comes to newer therapies, cost, and accessibility of therapies.
Health Care Utilization Rates Among Patients With NMOSD
Experts in neurology share their experiences with how patients with NMOSD are utilizing health care, and helping patients achieve optimal care.
Raising NMOSD Awareness Through Continued Education
Mirla Avila, MD, leads a discussion on the impact of NMOSD on women’s health and the role of continued education for physicians.
Psychosomatic Presentations of NMOSD
Drs Michael Levy, Mirla Avila, Mitzi Williams, and Michael Yeaman assess atypical presentations of NMOSD and the importance of building trust in a patient-provider relationship.
Role of Multidisciplinary Management in NMOSD
Mirla Avila, MD; Mitzi Williams, MD; Michael Levy, MD, PhD; and Michael Yeaman, PhD, review the role of a multidisciplinary team and gaps in the chain of care in the management of NMOSD.
Considerations for NMOSD Diagnosis
Experts in neurology share considerations and challenges for health care providers in diagnosing NMOSD, including education for non neurology health care providers and available diagnostic assays.
Disease Burden and Quality of Life for NMOSD
Mitzi Williams, MD, leads a discussion on the impact of the disease on quality of life for patients with NMOSD and their families.
Clinical Presentation of NMOSD and Overcoming Barriers to Access to Care
Mirla Avila, MD; Michael Levy, MD, PhD; and Mitzi Williams, MD, share the clinical presentation and progression of NMOSD among various racial and ethnic groups and highlight the effects of socioeconomic disparities and personal barriers on access to proper care.
Pathogenesis of NMOSD
Drs Mitzi Williams, Mirla Avila, and Michael Levy comment on the differences in pathogenesis in various patient populations affected by NMOSD as it relates to genetics, comorbidities, and immune tolerance.
Global Prevalence and Incidence of NMOSD
Michael Levy, MD, PhD; Mitzi Williams, MD; and Mirla Avila, MD, examine the genetic, behavioral, and cultural determinants of NMOSD prevalence and incidence.
Mary Schroth, MD: Cure SMA’s Ongoing Advocacy Initiatives
The chief medical officer at Cure SMA spoke to the ongoing work that the organization does in advocating for patients with spinal muscular atrophy, particularly for newborn screening.
GW Submits sNDA for CBD in Tuberous Sclerosis Complex
This additional application, supported by data from the GWPCARE6 trial, seeks to expand the indication of cannabidiol to include seizures associated with tuberous sclerosis complex.
Satralizumab BLA Accepted by FDA for Treatment of NMOSD
Study data demonstrates that treatment with satralizumab reduces risk of relapses in patients with neuromyelitis optica spectrum disorder.
FDA Rejects Duchenne Muscular Dystrophy Drug Golodirsen, Citing Safety Concerns
The regulatory agency cited 2 concerns in the complete response letter: the risk of infections related to intravenous infusion ports and renal toxicity.
Developing Targeted Therapeutics in Angelman Syndrome
The genomic revolution has led to increasing opportunities to address complex neurodevelopmental conditions, taking a genetics-first approach.
Genetic Testing for Huntington Disease
The profound consequences of the results guide decisions about testing. Who should be tested? And, just as important, who should not?
7 New Drugs for Neurologists
Here’s a brief look at therapies for neurological disorders that the FDA has approved within the past 6 months.
Teenager Who Sleeps Up to 20 Hours a Day
EEG and brain MRI findings are normal-what do you suspect?
Neuropsychiatric Symptoms in Huntington Disease: A 5-Question Quiz
Are you up-to-date on recent guidelines for the management of agitation, anxiety, apathy, psychosis, and sleep disorders in patients with Huntington disease? Take this brief quiz to find out.
New Guidelines on Management of Neuropsychiatric Symptoms in Huntington Disease
Some good news about Huntington disease: most of the behavioral symptoms can be managed with treatments developed for other conditions.
5 Qs on Vaccines and Guillain-Barre Syndrome
What is the most common risk factor for Guillain-Barré Syndrome? Plus 4 other quick questions to test your knowledge.
Case Report: Woman With Wide Gait and Loss of Balance
A 32-year-old woman presents with common symptoms that made up a rare diagnosis never seen by the neurologist in a decades-long career.
Can CoQ10 Benefit Primary Periodic Paralysis?
Some studies have suggested that, over the long-term, CoQ10 may increase type 2 muscle fibers, which are sometimes atrophied in individuals with PPP.
Hypokalemia, Paralysis, Myalgia, and Tea-colored Urine: What’s the Diagnosis?
A patient presented to the hospital with sudden-onset flaccid muscle weakness. Her family history was notable for sudden cardiac death of unknown etiology.
Exploring Recurrent Isolated Sleep Paralysis
Strategies and take-home points on sleep paralysis and its counterpart, isolated sleep paralysis, a REM sleep-related parasomnia commonly associated with intense fear and anxiety.
The Jack-O’-Lantern Sign: A Case Study
Dengue infection predominantly causes arthritis, fever, headache, and rash; hemorrhagic and neurologic manifestations may also result. What was the prognosis for this patient?
Hydrochlorthiazide: Not Only for Hyperkalemic Periodic Paralysis?
A young child’s neurological exam was notable for symmetrical decreased muscle strength and absence of deep tendon reflexes in both lower extremities. Learn about the case here.
Transient Paralysis, Cardiac Arrythmia, Facial Abnormalities: What’s the Diagnosis?
A 47-year-old man presented with a longstanding history of recurrent transient episodes of muscular weakness. What’s your diagnosis?
2 Clarke Drive Cranbury, NJ 08512